81 related articles for article (PubMed ID: 12866575)
1. p65 and c-erbB2 genes expression in breast tumors: comparison with some histological typing, grading and clinical staging.
Balcerczak E; Mirowski M; Jesionek-Kupnicka D; Bartkowiak J; Kubiak R; Wierzbicki R
J Exp Clin Cancer Res; 2003 Jun; 22(2):247-53. PubMed ID: 12866575
[TBL] [Abstract][Full Text] [Related]
2. Usefulness of polyclonal antibodies raised against P65 oncofetal protein in immunohistochemical diagnosis of ductal breast cancer.
Niewiadomska H; Mirowski M; Switalska J; Balcerczak E; Kubiak R; Wierzbicki R
J Exp Clin Cancer Res; 2004 Mar; 23(1):113-9. PubMed ID: 15149159
[TBL] [Abstract][Full Text] [Related]
3. [Relationship of oncogene C-erbB2 expression to ER, PR and PS2 in breast cancer and its prognostic significance].
Yang JQ; Chen L; Xing TY
Sichuan Da Xue Xue Bao Yi Xue Ban; 2004 May; 35(3):334-6, 357. PubMed ID: 15181828
[TBL] [Abstract][Full Text] [Related]
4. [Immunohistochemical study on the expression of c-erbB2 oncoprotein in breast tumors].
Zhang Z; Xu G; Liu S
Zhonghua Zhong Liu Za Zhi; 1997 Jul; 19(4):287-9. PubMed ID: 11038761
[TBL] [Abstract][Full Text] [Related]
5. [Expression of estrogen and progesterone receptors and HER-2 by breast cancer cells].
Zaĭrat'iants OV; Kolobov SV; Akopian IG; Opalenov KV; Barsanova TG
Arkh Patol; 2004; 66(5):9-12. PubMed ID: 15575377
[TBL] [Abstract][Full Text] [Related]
6. Presence of erbB2 mRNA in the plasma of breast cancer patients is associated with circulating tumor cells and negative estrogen and progesterone receptor status.
Xu Y; Yao L; Li H; Ouyang T; Li J; Wang T; Fan Z; Lin B; Lu Y; Larsson O; Xie Y
Breast Cancer Res Treat; 2006 May; 97(1):49-55. PubMed ID: 16319978
[TBL] [Abstract][Full Text] [Related]
7. Expression of p65, DD3 and c-erbB2 genes in prostate cancer.
Balcerczak E; Mirowski M; Sasor A; Wierzbicki R
Neoplasma; 2003; 50(2):97-101. PubMed ID: 12740642
[TBL] [Abstract][Full Text] [Related]
8. Comparison of extracellular matrix and apoptotic markers between benign lesions and carcinomas in human breast.
Vasaturo F; Sallusti E; Gradilone A; Malacrino C; Nardo T; Avagnano G; Aglianò AM; Granato T; De Vincenzi B; Coppotelli G; Marzullo A; Soda G; Simonelli L; Modesti M; Scarpa S
Int J Oncol; 2005 Oct; 27(4):1005-11. PubMed ID: 16142317
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical analysis of expression of a 65 kDa oncofetal protein (p65), epidermal growth factor receptor (EGFR), oncogene c-erb B2 and tumor suppressor gene p53 protein products in breast cancer patients.
Niewiadomska H; Mirowski M; Stempień M; Błoński JZ; Czyz W; Switalska J; Matyga E; Hanausek M; Wierzbicki R
Neoplasma; 2000; 47(1):8-14. PubMed ID: 10870681
[TBL] [Abstract][Full Text] [Related]
10. Relevance of c-erbB2, PLU-1 and survivin mRNA expression to diagnostic assessment of breast cancer.
Izawa A; Kobayashi D; Nasu S; Saito K; Moriai R; Asanuma K; Nakamura M; Yagihashi A; Watanabe N
Anticancer Res; 2002; 22(5):2965-9. PubMed ID: 12530026
[TBL] [Abstract][Full Text] [Related]
11. RET finger protein expression in invasive breast carcinoma: relationship between RFP and ErbB2 expression.
Tezel GG; Uner A; Yildiz I; Guler G; Takahashi M
Pathol Res Pract; 2009; 205(6):403-8. PubMed ID: 19232840
[TBL] [Abstract][Full Text] [Related]
12. Altered expression of metastasis-associated and regulatory molecules in effusions from breast cancer patients: a novel model for tumor progression.
Davidson B; Konstantinovsky S; Nielsen S; Dong HP; Berner A; Vyberg M; Reich R
Clin Cancer Res; 2004 Nov; 10(21):7335-46. PubMed ID: 15534110
[TBL] [Abstract][Full Text] [Related]
13. Expression of the p65 gene in patients with colorectal cancer: comparison with some histological typing, grading and clinical staging.
Balcerczak M; Balcerczak E; Pasz-Walczak G; Kordek R; Mirowski M
Eur J Surg Oncol; 2004 Apr; 30(3):266-70. PubMed ID: 15028307
[TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
[TBL] [Abstract][Full Text] [Related]
15. Correlation between genetic and biological aspects in primary non-metastatic breast cancers and corresponding synchronous axillary lymph node metastasis.
D'Andrea MR; Limiti MR; Bari M; Zambenedetti P; Montagutti A; Ricci F; Pappagallo GL; Sartori D; Vinante O; Mingazzini PL
Breast Cancer Res Treat; 2007 Mar; 101(3):279-84. PubMed ID: 16835704
[TBL] [Abstract][Full Text] [Related]
16. Tumor gene expression and prognosis in breast cancer patients with 10 or more positive lymph nodes.
Cobleigh MA; Tabesh B; Bitterman P; Baker J; Cronin M; Liu ML; Borchik R; Mosquera JM; Walker MG; Shak S
Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8623-31. PubMed ID: 16361546
[TBL] [Abstract][Full Text] [Related]
17. Alterations of estrogen receptors, progesterone receptors and c-erbB2 oncogene protein expression in ductal carcinomas of the breast.
Hussein MR; Abd-Elwahed SR; Abdulwahed AR
Cell Biol Int; 2008 Jun; 32(6):698-707. PubMed ID: 18296077
[TBL] [Abstract][Full Text] [Related]
18. Reduced expression of the breast cancer metastasis suppressor 1 mRNA is correlated with poor progress in breast cancer.
Zhang Z; Yamashita H; Toyama T; Yamamoto Y; Kawasoe T; Iwase H
Clin Cancer Res; 2006 Nov; 12(21):6410-4. PubMed ID: 17085653
[TBL] [Abstract][Full Text] [Related]
19. Detection of hepatocyte growth factor/scatter factor receptor (c-Met) and MUC1 from the axillary fluid drainage in patients after breast cancer surgery.
Greenberg R; Barnea Y; Schneebaum S; Kashtan H; Kaplan O; Skornik Y
Isr Med Assoc J; 2003 Sep; 5(9):649-52. PubMed ID: 14509156
[TBL] [Abstract][Full Text] [Related]
20. Prognostic role of a multigene reverse transcriptase-PCR assay in patients with node-negative breast cancer not receiving adjuvant systemic therapy.
Esteva FJ; Sahin AA; Cristofanilli M; Coombes K; Lee SJ; Baker J; Cronin M; Walker M; Watson D; Shak S; Hortobagyi GN
Clin Cancer Res; 2005 May; 11(9):3315-9. PubMed ID: 15867229
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
